As for therapeutic BMVs for cancers, OMVs are engineered with siRNA targeting kinesin spindle protein (KSP), which can target and kill cancer cells in a cell‐specific manner.[223] Moreover, a mutant E. coli strain was engineered to generate OMVs with a human epidermal growth factor receptor 2 (HER2)‐specific affibody in the membrane as a targeting ligand. The gene discussed is ERBB2; the disease is cancer.